[144] Corcept Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

On July 1, 2025, Dogwood Therapeutics, Inc. (ticker DWTX) filed a Form 4 disclosing that its Chief Executive Officer and Director, Gregory Scott Duncan, received a grant of 40,000 stock options on June 27, 2025. The options carry an exercise price of $4.71 per share, become exercisable one-third on June 27, 2026, and thereafter vest in equal monthly installments over 24 months, with an expiration date of June 27, 2035. Following this grant, Mr. Duncan beneficially owns 40,000 derivative securities directly. No shares of common stock were bought or sold, and there were no disposals of derivative securities. The filing represents routine executive compensation disclosure rather than a market-moving transaction.

Insights

Senior Equity Analyst

TL;DR: Routine option grant; neutral impact on valuation.

This Form 4 records a standard incentive award to CEO Greg Duncan—40 k options at $4.71, vesting over three years. Such grants are common for retention and alignment purposes and do not change share count today; potential dilution is immaterial relative to typical small-cap option pools. No open-market buying or selling occurred, so the filing offers no directional signal on management’s view of intrinsic value. Overall, the disclosure is administrative and should not materially influence DWTX’s investment thesis.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St Louis MO 63102	5000	367000.00	106040000	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2025	Stock Option Exercise	Corcept Therapeutics Inc.			5000	07/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	04/01/2025	650	74443.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	05/01/2025	9350	672781.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/02/2025	5000	390218.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transaction did Dogwood Therapeutics (DWTX) report on Form 4?

CEO Greg Duncan received 40,000 stock options at an exercise price of $4.71 on June 27, 2025.

Did the CEO of Dogwood Therapeutics buy or sell any common shares?

No. The Form 4 shows only an option grant; there were no purchases or sales of common stock.

What is the vesting schedule for the 40,000 options granted to Greg Duncan?

One-third vests on June 27, 2026, with the remainder vesting 1/24 monthly thereafter until fully vested.

When do the granted Dogwood Therapeutics options expire?

The options expire on June 27, 2035 if not exercised earlier.

How many derivative securities does the Dogwood CEO own after this filing?

Following the transaction, Greg Duncan beneficially owns 40,000 derivative securities (options) directly.